Sign In
Buy DTCFF
$0.410
-0.0624 (-13.20%)
At Close: Jun 03, 2026
Defence Therapeutics Appoints Seasoned Biopharmaceutical Executive Dr John Beaver to Its Board of Directors
03:15am, Wednesday, 03'rd Jun 2026
Montreal, Quebec--(Newsfile Corp. - June 3, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology and precision intracel
Defence Therapeutics Appoints Antibody Drug Conjugates Pioneer Dr. John Lambert to Its Board of Directors
03:15am, Monday, 01'st Jun 2026
Montreal, Quebec--(Newsfile Corp. - June 1, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology and precision intrace
Defence Therapeutics Strengthens Its Scientific Advisory Board with the Appointment of Dr. Sarkis Meterissian
04:30pm, Friday, 29'th May 2026
Montreal, Quebec--(Newsfile Corp. - May 29, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology and precision intra
Defence Therapeutics Enhances In-House ADC Development Platform with Expanded Analytical and Cellular Testing Capabilities
03:15am, Tuesday, 19'th May 2026
Montreal, Quebec--(Newsfile Corp. - May 19, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology and precision intracell
Defence Therapeutics Announces Grant of Restricted Stock Units
06:30pm, Friday, 24'th Apr 2026
Montreal, Quebec--(Newsfile Corp. - April 24, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC), ("Defence" or the "Company"), a publicly traded biotechnology and precision intr
Defence Therapeutics Announces Warrant Terms Amendment
06:00pm, Friday, 20'th Mar 2026
Montreal, Quebec--(Newsfile Corp. - March 20, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology and precision intra
Defence Therapeutics Announces Closing of Private Placement of Units for Gross Proceeds of $9,595,000
03:15am, Monday, 09'th Mar 2026
Montreal, Quebec--(Newsfile Corp. - March 9, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC), ("Defence" or the "Company"), a publicly traded biotechnology and precision intra
Defence Therapeutics to Showcase Accum Platform at Key International Industry Events in March
03:15am, Monday, 02'nd Mar 2026
Montreal, Quebec--(Newsfile Corp. - March 2, 2026) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a publicly traded biotechnology company advancing next
Defence Therapeutics Announces Private Placement of Units for Proceeds of up to $11 Million
05:00pm, Friday, 27'th Feb 2026
Montreal, Quebec--(Newsfile Corp. - February 27, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology and precision in
Defence Therapeutics Aligns Accum ADC Strategy Through Multidisciplinary Scientific Advisory Board
03:15am, Tuesday, 10'th Feb 2026
Montreal, Quebec--(Newsfile Corp. - February 10, 2026) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a publicly traded biotechnology and precision int
Defence Therapeutics Expands Collaboration with Canadian Nuclear Laboratories to Accelerate Its Proprietary Radiopharmaceutical Pipeline
08:40am, Wednesday, 28'th Jan 2026
Montreal, Quebec--(Newsfile Corp. - January 28, 2026) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a publicly traded biotechnology and precision intra
Defence Therapeutics (OTCMKTS:DTCFF) Stock Price Down 4.9% – Here’s Why
03:33am, Thursday, 22'nd Jan 2026
Defence Therapeutics Inc. (OTCMKTS:DTCFF - Get Free Report)'s share price dropped 4.9% during mid-day trading on Wednesday. The company traded as low as $0.3446 and last traded at $0.4456. Approximate
Defence Therapeutics Sharpens Strategic Focus on Precision Drug Delivery to Unlock the Full Potential of Cancer Biologics
03:15am, Wednesday, 21'st Jan 2026
Montreal, Quebec--(Newsfile Corp. - January 21, 2026) - Defence Therapeutics Inc., (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a publicly traded biotechnology company, today ann
Defence Therapeutics (OTCMKTS:DTCFF) Shares Down 5.9% – Here’s What Happened
02:07am, Saturday, 27'th Dec 2025
Defence Therapeutics Inc. (OTCMKTS:DTCFF - Get Free Report)'s stock price dropped 5.9% during mid-day trading on Friday. The company traded as low as $0.5647 and last traded at $0.5647. Approximately
Defence Therapeutics to Present at the Life Sciences Virtual Investor Forum December 11th
08:35am, Thursday, 11'th Dec 2025
Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com Company invites individual and institutional investors, as
